Literature DB >> 12525295

Update on Kaposi's Sarcoma: A Gammaherpesvirus- induced Malignancy.

Pallavi P. Kumar1, Richard F. Little, Robert Yarchoan.   

Abstract

Since the beginning of the AIDS epidemic, Kaposi's sarcoma (KS) has been one of the most visible manifestations of this disease and one of the most distressing for affected patients. The discovery in 1994 of a new gammaherpesvirus, called Kaposi's sarcoma-associated herpesvirus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy. In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in countries where it is available and on the course of established disease. Finally, recent advances in our understanding of angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches that are now under development.

Entities:  

Year:  2003        PMID: 12525295     DOI: 10.1007/s11908-003-0069-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  53 in total

1.  Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.

Authors:  S Walmsley; D W Northfelt; B Melosky; M Conant; A E Friedman-Kien; B Wagner
Journal:  J Acquir Immune Defic Syndr       Date:  1999-11-01       Impact factor: 3.731

2.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

3.  Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors.

Authors:  N Sidell; T Taga; T Hirano; T Kishimoto; A Saxon
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

4.  Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Authors:  C Dupont; E Vasseur; A Beauchet; P Aegerter; H Berthé; P de Truchis; D Zucman; E Rouveix; P Saiag
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

5.  Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.

Authors:  John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Mucosal shedding of human herpesvirus 8 in men.

Authors:  J Pauk; M L Huang; S J Brodie; A Wald; D M Koelle; T Schacker; C Celum; S Selke; L Corey
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

Review 7.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

8.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

9.  Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.

Authors:  Steven A Miles; Bruce J Dezube; Jeannette Y Lee; Susan E Krown; Mary Ann Fletcher; M Wayne Saville; Lawrence Kaplan; Jerome Groopman; David T Scadden; Timothy Cooley; Jamie Von Roenn; Alvin Friedman-Kien
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

10.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.